In breast cancer, there exists a concordance between heightened TGF‐β–Smad2 pathway activation and the DNA methylation‐mediated silencing of CDH1, implicating a complex interplay between signaling pathways and epigenetic modifications in the cancer metastasis narrative. The gene discussed is TGFB1; the disease is breast carcinoma.